UCB (OTCMKTS:UCBJY) Rating Increased to Strong-Buy at Zacks Research

Zacks Research upgraded shares of UCB (OTCMKTS:UCBJY) from a hold rating to a strong-buy rating in a research report report published on Tuesday morning,Zacks.com reports.

A number of other equities research analysts have also issued reports on the stock. Jefferies Financial Group raised shares of UCB from a “moderate sell” rating to a “hold” rating in a report on Monday. Barclays cut shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy”.

UCB Stock Up 2.8%

Shares of UCBJY opened at $132.20 on Tuesday. The stock has a 50 day moving average price of $142.79 and a 200 day moving average price of $146.99. UCB has a one year low of $106.24 and a one year high of $168.76. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.